Antonio Piga

List of Publications by Year
in descending order

63	7,072	109321	123424
papers	citations	35 h-index	61 g-index

63	63	63	3861
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, 89, 1187-93.	3.5	772
2	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	1.4	636
3	SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR. Lancet, The, 1989, 334, 27-30.	13.7	520
4	Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 2006, 107, 3738-3744.	1.4	424
5	Results of Long-Term Iron-Chelating Therapy. Acta Haematologica, 1996, 95, 26-36.	1.4	348
6	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 2006, 107, 3733-3737.	1.4	338
7	Survival and Disease Complications in Thalassemia Major. Annals of the New York Academy of Sciences, 1998, 850, 227-231.	3.8	312
8	Cardiovascular Function and Treatment in Î²-Thalassemia Major. Circulation, 2013, 128, 281-308.	1.6	301
9	Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 2003, 102, 1583-1587.	1.4	284
10	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
11	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91, 873-80.	3.5	210
12	The safety and effectiveness of deferiprone in a largeâ€scale, 3â€year study in Italian patients. British Journal of Haematology, 2002, 118, 330-336.	2.5	192
13	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, 93, 741-752.	3.5	182
14	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 2011, 118, 884-893.	1.4	181
15	Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood, 2002, 100, 1566-1569.	1.4	162
16	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	2.5	147
17	High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 2009, 84, 29-33.	4.1	128
18	Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Movement Disorders, 2011, 26, 1755-1759.	3.9	125

#	Article	IF	Citations
19	Challenges of blood transfusions in Î²-thalassemia. Blood Reviews, 2019, 37, 100588.	5.7	123
20	Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 2006, 91, 1343-51.	3.5	109
21	Pregnancy and Â-thalassemia: an Italian multicenter experience. Haematologica, 2010, 95, 376-381.	3.5	103
22	Efficacy and safety of deferasirox doses of >30â€ƒmg/kg per d in patients with transfusionâ€dependent anaemia and iron overload. British Journal of Haematology, 2009, 147, 752-759.	2.5	101
23	Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with Î²-thalassaemia major: application of SQUID biomagnetic liver susceptometry. British Journal of Haematology, 2003, 121, 938-948.	2.5	100
24	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in Î²-thalassemia major (CORDELIA). Blood, 2014, 123, 1447-1454.	1.4	97
25	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	2.5	69
26	Prevalence and distribution of iron overload in patients with transfusionâ€dependent anemias differs across geographic regions: results from the <scp>CORDELIA</scp> study. European Journal of Haematology, 2015, 95, 244-253.	2.2	61
27	Monitoring Long-Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry. Annals of the New York Academy of Sciences, 2005, 1054, 350-357.	3.8	57
28	Amlodipine Reduces Cardiac Iron Overload in Patients with Thalassemia Major: A Pilot Trial. American Journal of Medicine, 2013, 126, 834-837.	1.5	51
29	Severe iron overload in Blackfanâ€Diamond anemia: A caseâ€control study. American Journal of Hematology, 2009, 84, 729-732.	4.1	48
30	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	1.4	48
31	A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood, 2016, 128, 1555-1561.	1.4	47
32	Sustained improvements in myocardial T2* over 2 years in severely ironâ€overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology, 2015, 90, 91-96.	4.1	43
33	A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone. Annals of the New York Academy of Sciences, 1998, 850, 223-226.	3.8	42
34	Deferiprone. Annals of the New York Academy of Sciences, 2010, 1202, 75-78.	3.8	40
35	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. Journal of Clinical Pharmacology, 2008, 48, 428-435.	2.0	36
36	Purging iron from the heart. British Journal of Haematology, 2004, 125, 545-551.	2.5	34

#	Article	IF	Citations
37	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 34.	3.3	32
38	Changing patterns of splenectomy in transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2011, 86, 808-810.	4.1	32
39	Current Status in Iron Chelation in Hemoglobinopathies. Current Molecular Medicine, 2008, 8, 663-674.	1.3	31
40	Assessment and management of iron overload in Î²â€thalassaemia major patients during the 21st century: a realâ€life experience from the <scp>I</scp>talian <scp>W</scp>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	2.5	31
41	Deferiprone therapy in homozygous human Î²-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. Translational Research, 1999, 133, 64-69.	2.3	29
42	A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 893-894, 127-133.	2.3	29
43	Deferasirox effect on renal haemodynamic parameters in patients with transfusionâ€dependent Î² thalassaemia. British Journal of Haematology, 2015, 168, 882-890.	2.5	27
44	Late Effects of Bone Marrow Transplantation for Thalassemiaa. Annals of the New York Academy of Sciences, 1998, 850, 294-299.	3.8	19
45	A Phase II Study with ICL670 (ExjadeÂ®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. Blood, 2004, 104, 3193-3193.	1.4	17
46	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. European Journal of Echocardiography, 2011, 12, 242-246.	2.3	16
47	Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics, 2016, 17, 571-582.	1.3	15
48	Atrial fibrillation in Î²-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options. Hemoglobin, 2018, 42, 189-193.	0.8	15
49	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics, 2017, 18, 539-554.	1.3	14
50	Liver stiffness assessed by transient elastography in patients with Î² thalassaemia major. Annals of Hepatology, 2016, 15, 410-417.	1.5	13
51	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Internal and Emergency Medicine, 2019, 14, 365-370.	2.0	13
52	Once-Daily Treatment with the Oral Iron Chelator ICL670 (ExjadeÂ®): Results of a Phase II Study in Pediatric Patients with Î²-Thalassemia Major.. Blood, 2004, 104, 3614-3614.	1.4	11
53	Deferasirox pharmacokinetic and toxicity correlation in Î²-thalassaemia major treatmentâ€. Journal of Pharmacy and Pharmacology, 2016, 68, 1417-1421.	2.4	9
54	Children of a lesser god or miracles? An emotional and behavioural profile of children born to mothers on dialysis in Italy: a multicentre nationwide study 2000â€“12. Nephrology Dialysis Transplantation, 2015, 30, 1193-1202.	0.7	8

#	Article	IF	Citations
55	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. Pharmacogenomics Journal, 2019, 19, 417-427.	2.0	6
56	Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. Scientific Reports, 2021, 11, 12581.	3.3	6
57	Deferasirox pharmacokinetic evaluation in Î²-thalassaemia paediatric patientsâ€. Journal of Pharmacy and Pharmacology, 2017, 69, 525-528.	2.4	5
58	Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major. Journal of Clinical Densitometry, 2018, 21, 507-516.	1.2	5
59	Clinical relevance of deferasirox trough levels in Î²â€thalassemia patients. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 213-216.	1.9	3
60	The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients. Journal of Cardiovascular Development and Disease, 2022, 9, 3.	1.6	3
61	Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfusion, 2021, 19, 261-268.	0.4	2
62	Agreement of liver iron quantification measurements with low Tc-SQUID biosusceptometers in Oakland, Torino and Hamburg. International Congress Series, 2007, 1300, 279-282.	0.2	0
63	Myocardial longitudinal strain as the first herald of cardiac impairment in very early iron overload state: an echocardiography and biosusceptometry study on beta-thalassemia patients. American Journal of Cardiovascular Disease, 2021, 11, 555-563.	0.5	0